|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
|Ticker||Company||Price||Change||Chg %||Mkt Cap|
You can purchase shares of Inhibikase Therapeutics (NASDAQ: IKT) through any online brokerage.
There are no as such competitors for Inhibikase Therapeutics.
The latest price target for Inhibikase Therapeutics (NASDAQ: IKT) was reported by JonesTrading on July 15, 2021. The analyst firm set a price target for 12.00 expecting IKT to rise to within 12 months (a possible 430.36% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $2.2626 last updated Today at 6:49:23 PM.
There are no upcoming dividends for Inhibikase Therapeutics.
There is no upcoming split for Inhibikase Therapeutics.
Inhibikase Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.